Health Care Select Sector SPDR Fund : XLV

XLV

Stock Data

$152.65

$0.36 (0.24%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

All XLV Articles

19 Articles

Thomas Richmond | Yesterday

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC,…

David Moadel | Jun 4, 2026 at 1:32 PM EDT

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

Health insurers are running higher in Thursday afternoon trading after a wave of bullish Wall Street analyst notes on the…

Tony Dong | May 20, 2026 at 8:30 AM EDT

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

2022 was a really weird year to be an investor. Even four years later, I still remember what happened. A…

Omor Ibne Ehsan | May 19, 2026 at 4:19 PM EDT

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by…

Austin Smith | Apr 29, 2026 at 7:23 AM EDT

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

Healthcare is supposed to be the place you hide. It is the fourth-largest slice of U.S. GDP at 8.9% in…

Michael Williams | Mar 26, 2026 at 2:32 PM EDT

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT),…

Joel South | Mar 17, 2026 at 11:56 AM EDT

Why One Analyst Thinks Johnson & Johnson Reaches $280

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) has been one of healthcare’s standout performers over the past year, with…

Tony Dong | Mar 9, 2026 at 9:33 AM EDT

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

Talk of a recession is once again dominating the headlines. The latest job report has just been released, showing a…

Austin Smith | Feb 18, 2026 at 5:32 AM EST

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of…

Joey Frenette | Jan 29, 2026 at 12:16 PM EST

2 Hot Sector ETFs Worth Buying in 2026

Index investors and so-called Bogleheads (those who love the Vanguard ETFs) may not be all too fond of the sector…

Michael Williams | Jan 29, 2026 at 8:20 AM EST

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs,…

John Seetoo | Jan 8, 2026 at 8:48 AM EST

3 Top ETFs To Profit As Investors Move Away From Big Tech in 2026

Defensive stocks are defined as the stocks in companies that are grouped in sectors supplying goods and services in constant…

Omor Ibne Ehsan | Dec 16, 2025 at 12:41 PM EST

These 3 Dividend ETFs Outperformed Every Market Crash Since 2000

If you are an investor who is securing profits and is buying up dividend ETFs to weather a possible downturn…

Rich Duprey | Mar 26, 2025 at 11:52 AM EDT

The 5 Biggest Risks to JEPI’s 7.4% Dividend Yield

The JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) has become a go-to for investors chasing steady income with a side of…

Joey Frenette | Mar 7, 2025 at 7:11 AM EST

At 35 I should know more about my Roth IRA than I do, but am risk-averse and worried about retirement

If you’re 35 and growing a bit anxious about the prospect of retirement, do not fret as many Millennials, some…

1 2

Health Care Select Sector SPDR Fund : XLV

XLV

$152.65

All XLV Articles

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Why One Analyst Thinks Johnson & Johnson Reaches $280

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

2 Hot Sector ETFs Worth Buying in 2026

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

3 Top ETFs To Profit As Investors Move Away From Big Tech in 2026

These 3 Dividend ETFs Outperformed Every Market Crash Since 2000

The 5 Biggest Risks to JEPI’s 7.4% Dividend Yield

At 35 I should know more about my Roth IRA than I do, but am risk-averse and worried about retirement

Apple Finally Released A Brand-New Siri. Then Its Share Price Cratered.

1 Plain-As-Day Dividend King to Buy and Never Sell That Has Increased Its Payout for 64 Consecutive Years

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old’s Medicare Costs

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later

Apple Finally Released A Brand-New Siri. Then Its Share Price Cratered.

1 Plain-As-Day Dividend King to Buy and Never Sell That Has Increased Its Payout for 64 Consecutive Years

Health Care Select Sector SPDR Fund : XLV

XLV

$152.65

All XLV Articles

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Why One Analyst Thinks Johnson & Johnson Reaches $280

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

2 Hot Sector ETFs Worth Buying in 2026

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

3 Top ETFs To Profit As Investors Move Away From Big Tech in 2026

These 3 Dividend ETFs Outperformed Every Market Crash Since 2000

The 5 Biggest Risks to JEPI’s 7.4% Dividend Yield

At 35 I should know more about my Roth IRA than I do, but am risk-averse and worried about retirement

Apple Finally Released A Brand-New Siri. Then Its Share Price Cratered.

1 Plain-As-Day Dividend King to Buy and Never Sell That Has Increased Its Payout for 64 Consecutive Years

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old’s Medicare Costs

Featured Reads

The RMD Trap: How a Single $95,000 Withdrawal Blindsided a 73-Year-Old's Medicare Costs

The Roth Conversion That Added $999.60 to a Retiree's Medicare Bill...Two Years Later